Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Summit Therapeutics (SMMT) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

SMMT Analyst Ratings

Moderate Buy
14Ratings
8Buy6Hold0Sell
Based on 14 analysts giving stock ratings to Summit Therapeutics in the past 3 months

SMMT Stock 12 Month Forecast

Mex$527.39▲(81.86% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Summit Therapeutics in the last 3 months. The average price target is MXN 527.39 with a high forecast of MXN 799.79 and a low forecast of MXN 221.34. The average price target represents a 81.86% change from the last price of MXN 290.00.
Highest Price TargetMex$799.79Average Price TargetMex$527.39Lowest Price TargetMex$221.34

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for MX:SMMT
Price TargetArticle
Wells FargoMex$557.99buy92.41%UpsideReiterated11/11/26
BernsteinMex$221.34hold-23.68%DownsideReiterated11/09/26
H.C. Wainwright―hold―Reiterated11/05/26
Stifel NicolausMex$706.79→Mex$688.19buy137.31%UpsideReiterated11/05/26
Leerink Partners Analyst forecast on MX:SMMTUnknown AnalystNot RankedLeerink PartnersMex$241.80hold-16.62%DownsideReiterated11/05/26
Piper SandlerMex$297.60hold2.62%UpsideReiterated11/05/26
Evercore ISIMex$632.39buy118.07%UpsideReiterated11/05/26
CitiMex$799.79buy175.79%UpsideReiterated11/05/26
BarclaysMex$372.00hold28.27%UpsideReiterated11/04/26
Goldman SachsMex$799.79buy175.79%UpsideReiterated11/04/26
UBSMex$613.79buy111.65%UpsideReiterated10/26/26
Jefferies―buy―Reiterated09/29/26
Clear StreetMex$576.59buy98.83%UpsideReiterated09/03/26
Wolfe Research―hold―Reiterated08/16/26
TD Cowen―buy―Reiterated07/27/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PTGXProtagonist Therapeutics
ESTAEstablishment Labs Holdings
MDWDMediwound
IMUXImmunic
OVIDOvid Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Summit Therapeutics

3 Months
Yigal Nochomovitz
Yigal NochomovitzCiti
Success Rate12/20 ratings generated profit
60%
Average Return
+10.02%
Follow Yigal Nochomovitz

Copying Yigal Nochomovitz's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +10.02% per trade.

1 Year
Bradley Canino
Bradley CaninoGuggenheim
Success Rate8/11 ratings generated profit
73%
Average Return
+144.81%
Follow Bradley Canino

Copying Bradley Canino's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +144.81% per trade.

2 Years
Bradley Canino
Bradley CaninoGuggenheim
Success Rate7/11 ratings generated profit
64%
Average Return
+95.13%
Follow Bradley Canino

Copying Bradley Canino's trades and holding each position for 2 Years would result in 63.64% of your transactions generating a profit, with an average return of +95.13% per trade.

SMMT Analyst Recommendation Trends

020406080Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
Monthly rating counts for SMMT
RatingJul 26Aug 26Sep 26Oct 26Nov 26
Strong Buy1815231819
Buy41433
Hold1215212120
Sell12110
Strong Sell20000
total3733494342

In the current month, SMMT has received 22 Buy Ratings, 20 Hold Ratings, and 0 Sell Ratings. SMMT average Analyst price target in the past 3 months is 527.39.

SMMT Financial Forecast

Mex$-11Mex$-9Mex$-7Mex$-5Mex$-3Q1 2026Q3 2026Q4 2026
HighMex$-3.91
ConsensusMex$-5.52
LowMex$-9.67

SMMT Earnings Forecast

Next quarter’s earnings estimate for SMMT is -MXN 5.52 with a range of -MXN 9.67 to -MXN 3.91. The previous quarter’s EPS was -MXN 4.84. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.

Mex$-1Mex$50.2MMex$100.4MMex$150.7MMex$200.9MQ1 2026Q3 2026Q4 2026
HighMex$201M
ConsensusMex$55.9M
LowMex$0.00

SMMT Sales Forecast

Next quarter’s sales forecast for SMMT is MXN 55.91M with a range of MXN 0 to MXN 200.88M. The previous quarter’s sales results were MXN 0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

SMMT Stock Forecast FAQ

What is MX:SMMT’s average 12-month price target, according to analysts?
Based on analyst ratings, Summit Therapeutics’s 12-month average price target is Mex$527.39.
What is MX:SMMT’s upside potential, based on the analysts’ average price target?
Summit Therapeutics has 81.86% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Summit Therapeutics a Buy, Sell or Hold?
Summit Therapeutics has a consensus rating of Moderate Buy, which is based on 8 buy ratings, 6 hold ratings and 0 sell ratings.
What is Summit Therapeutics’s share price target?
The average share price target for Summit Therapeutics is Mex$527.39. This is based on 14 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is Mex$799.79, and the lowest forecast is Mex$221.34. The average share price target represents a 81.86% increase from the current price of Mex$290.
What do analysts say about Summit Therapeutics?
Summit Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Street analysts.
How can I buy shares of Summit Therapeutics?
To buy shares of MX:SMMT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.